BSE:524774

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. More Details


Snowflake Analysis

Flawless balance sheet with questionable track record.

Share Price & News

How has NGL Fine-Chem's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 524774's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.3%

524774

-0.8%

IN Pharmaceuticals

1.4%

IN Market


1 Year Return

78.0%

524774

48.4%

IN Pharmaceuticals

2.8%

IN Market

Return vs Industry: 524774 exceeded the Indian Pharmaceuticals industry which returned 48.6% over the past year.

Return vs Market: 524774 exceeded the Indian Market which returned 2.6% over the past year.


Shareholder returns

524774IndustryMarket
7 Day10.3%-0.8%1.4%
30 Day21.0%3.0%8.0%
90 Day112.0%12.3%7.8%
1 Year78.7%78.0%50.2%48.4%4.5%2.8%
3 Year156.1%154.1%25.7%22.3%-0.5%-5.3%
5 Year279.6%276.7%0.5%-3.1%41.5%31.0%

Price Volatility Vs. Market

How volatile is NGL Fine-Chem's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NGL Fine-Chem undervalued compared to its fair value and its price relative to the market?

43.7x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 524774 (₹886) is trading above our estimate of fair value (₹50.39)

Significantly Below Fair Value: 524774 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 524774 is poor value based on its PE Ratio (43.7x) compared to the IN Pharmaceuticals industry average (22.8x).

PE vs Market: 524774 is poor value based on its PE Ratio (43.7x) compared to the Indian market (16.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 524774's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 524774 is overvalued based on its PB Ratio (5.5x) compared to the IN Pharmaceuticals industry average (2.2x).


Next Steps

Future Growth

How is NGL Fine-Chem forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NGL Fine-Chem has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has NGL Fine-Chem performed over the past 5 years?

7.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 524774 has high quality earnings.

Growing Profit Margin: 524774's current net profit margins (8.2%) are lower than last year (12.8%).


Past Earnings Growth Analysis

Earnings Trend: 524774's earnings have grown by 7.9% per year over the past 5 years.

Accelerating Growth: 524774's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 524774 had negative earnings growth (-38.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.7%).


Return on Equity

High ROE: 524774's Return on Equity (12.7%) is considered low.


Next Steps

Financial Health

How is NGL Fine-Chem's financial position?


Financial Position Analysis

Short Term Liabilities: 524774's short term assets (₹808.6M) exceed its short term liabilities (₹430.4M).

Long Term Liabilities: 524774's short term assets (₹808.6M) exceed its long term liabilities (₹116.2M).


Debt to Equity History and Analysis

Debt Level: 524774's debt to equity ratio (28.5%) is considered satisfactory.

Reducing Debt: 524774's debt to equity ratio has reduced from 40.6% to 28.5% over the past 5 years.

Debt Coverage: 524774's debt is well covered by operating cash flow (72.5%).

Interest Coverage: 524774's interest payments on its debt are well covered by EBIT (8.6x coverage).


Balance Sheet


Next Steps

Dividend

What is NGL Fine-Chem current dividend yield, its reliability and sustainability?

0.20%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 524774's dividend (0.2%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.55%).

High Dividend: 524774's dividend (0.2%) is low compared to the top 25% of dividend payers in the Indian market (2.28%).


Stability and Growth of Payments

Stable Dividend: 524774 is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.

Growing Dividend: 524774 is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 524774 is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 524774's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.1yrs

Average board tenure


CEO

Rahul Nachane (56 yo)

no data

Tenure

₹12,342,000

Compensation

Mr. Rahul Jayant Nachane, B. Com, ACA, MMS, DBF has been Managing Director of NGL Fine-Chem Ltd. since June 1, 2006 and serves as its Chief Executive Officer. Mr. Nachane serves as the Chief Ethics Counse ...


CEO Compensation Analysis

Compensation vs Market: Rahul's total compensation ($USD167.19K) is above average for companies of similar size in the Indian market ($USD55.56K).

Compensation vs Earnings: Rahul's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Rahul Nachane
CEO, MDno data₹12.34m17.54%
₹ 959.9m
Rajesh Lawande
Whole Time Director & CFO15.33yrs₹12.20m21.89%
₹ 1.2b
Milind Shinde
Independent Chairmanno data₹245.00kno data
Ajita Nachane
Non Executive Woman Director6.08yrs₹225.00k11.55%
₹ 632.1m
Jayaram Sitaram
Independent Non-Executive Director5.17yrs₹240.00k0.38%
₹ 20.9m
K. Subramanian
Non-Executive Independent Director0.67yrno datano data

6.1yrs

Average Tenure

54.5yo

Average Age

Experienced Board: 524774's board of directors are considered experienced (6.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

NGL Fine-Chem Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NGL Fine-Chem Limited
  • Ticker: 524774
  • Exchange: BSE
  • Founded: 1981
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹5.474b
  • Shares outstanding: 6.18m
  • Website: https://www.nglfinechem.com

Number of Employees


Location

  • NGL Fine-Chem Limited
  • 301, E Square
  • Subhash Road
  • Mumbai
  • Maharashtra
  • 400057
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
524774BSE (Mumbai Stock Exchange)YesEquity SharesININRDec 2004

Biography

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. The company offers active pharmaceutical ingredients, such as diminazene ace ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/24 12:40
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.